Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees

Executive Summary

FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003

You may also be interested in...

Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?

FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5

Accelerated Approval Standards Will Be Advisory Committee Topic In March

FDA is planning an advisory committee meeting to discuss the accelerated approval process for oncologic agents

FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels

FDA will reduce its total advisory committee count to 30 with the termination of the Pharmacy Compounding and Medical Imaging Drugs Advisory Committees

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts